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A 50-year-old woman with incidentally detected multiple gastric polyps and biopsy-proven neuroendocrine tumor (NET) was referred 
to our hospital. More than 10 polypoid lesions (less than 15 mm) with normal gastric mucosa were detected from the gastric body to the 
fundus. The serum level of gastrin was within the normal limits. There was no evidence of atrophic changes on endoscopy and serologic 
marker as pepsinogen I/II ratio. Computed tomography of the abdomen and pelvis revealed no evidence of metastatic lesions. She 
refused surgery, and we performed endoscopic polypectomy for almost all the gastric polyps that were greater than 5 mm. Although 
the histological examination revealed that all the removed polys were diagnosed as NET G1, three of them extended to the lateral or 
vertical resection margins, while two exhibited lymphovascular invasion. A follow-up upper endoscopy that was performed 6 months 
after the diagnosis showed multiple remnant gastric polyps that were suggestive of remnant gastric NET. Clin Endosc  2015;48:431-435
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INTRODUCTION
Gastric neuroendocrine tumors (NETs), previously referred 
to as gastric carcinoids, are rare neoplasms that account for 
0.6% to 2% of all identified gastric polyps and 8.7% of all 
gastrointestinal NETs.1,2 The incidence of gastric NETs has in-
creased over the last 50 years, partly due to the improvement 
of endoscopic surveillance and heightened awareness.1,3
Gastric NETs are usually classified into three types based 
on the background gastric pathology. Type 1 arises in the 
presence of achlorhydric atrophic body gastritis (ABG), type 
2 is associated with the Zollinger-Ellison syndrome (ZES) and 
multiple endocrine neoplasia type 1 (MEN-1), while type 3 
includes the “sporadic” NET in the absence of a specific back-
ground of pathologic changes.4 This classification plays an 
important clinical role when approaching a gastric NET, not 
only due to the possible coexistence of a predisposing condi-
tion such as ABG and ZES, but also due to the implications in 
tumor behavior and the prognosis of the patient.
Type 3 gastric NET represents 14% to 25% of gastric NETs 
and have poor prognosis with the highest rate of distant me-
tastasis.5,6 They mostly are large (>2 cm) solitary lesions arising 
in the normal surrounding mucosa.7 In this case, we describe 
a patient with multicentric (more than 10) small gastric NETs 
identified as type 3.
CASE REPORT
A 50-year-old woman underwent an esophagogastroduode-
noscopy (EGD) for a health check-up. More than 10 polypoid 
lesions of the stomach were discovered, and the biopsy speci-
mens from the gastric polyps demonstrated grade 1 (G1) NET, 
according to World health Organization classification.8 She 
was referred to our hospital for proper management of the 
gastric NETs.
She had no carcinoid symptoms such as flushes or diarrhea, 
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had no significant medical history, and did not previously re-
ceive any proton pump inhibitors or H2 receptor antagonists. 
Interestingly, her sister also had gastric NETs. The results of 
the peripheral blood and routine chemistry tests were within 
the normal limits. The serum level of fasting gastrin was 85.2 
pg/mL (normal rage, 0 to 90). The serum level of pepsinogen 
I (PG I) was 70.7 ng/mL and that of pepsinogen II (PG II) 
was 10.9 ng/mL with the PG I/II ratio being 6.48 (positive 
range, PG I ≤70 ng/mL and PG I/II ≤3.0 ratio). Helicobacter 
pylori were not detected with rapid urease test and anti-H. 
pylori immunoglobulin G antibody level was 9.1 AU/mL with 
equivocal range (negative range, <8.0 AU/mL). On EGD (A5 
CE0 mode, GIF-Q260 scope; Olympus Optical, Tokyo, Japan), 
multiple polypoid lesions were detected mainly around the 
greater curvature of the gastric body to the fundus. Some pol-
yps accompanied the erythematous mucosal change, and the 
maximum diameter of polyps was less than 15 mm (Fig. 1A, 
B). Focal granular mucosal change was detected in the gastric 
body, but there was no evidence of atrophic gastritis in the an-
trum (Fig. 1C). A computed tomography scan of the abdomen 
and pelvis revealed multiple enhancing polypoid lesions in the 
stomach without any evidence of metastatic lesions.
She refused surgery, and we decided to perform endoscopic 
polypectomy. Polypectomy was performed without compli-
cations and almost all the gastric polyps that were greater 
than 5 mm in size were removed. A histological examination 
revealed that all the removed polys were NET GI, which was 
composed of uniform cells with round or ovoid nuclei and 
scanty eosinophilic cytoplasm, proliferating in a trabecular or 
glandular pattern (Fig. 2). The tumor cells invaded the submu-
cosal layer, diffusely staining for chromogranin A. The mitotic 
count was absent and the Ki-67 index was less than 1%. Most 
significantly, three of the polyps extended to the lateral or ver-
tical resection margins and two exhibited lymphovascular in-
vasion. Fundic gland atrophy was not detected from random 
biopsies on the greater curvature of the upper body, mid-body, 
and antrum. We diagnosed this patient with multicentric type 
3 gastric NETs. After the procedure, she still refused surgery 
despite the high risk of metastasis and tumor-related death. 
Follow-up EGD at 6 months after diagnosis showed multiple 
remnant gastric polyps suggestive of gastric NETs (Fig. 3).
C
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Fig. 1. Endoscopic findings. Esophagogastroduodenoscopy re-
vealed multiple polypoid lesions (less than 15 mm) located on lower 
body to fundus of stomach with normal gastric mucosa (A, B). There 
was no evidence of atrophic gastritis in the antrum (C). 
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DISCUSSION
Gastric NETs were first categorized into three types in 1993 
by Rindi et al.4 Type 1 and 2 are related to the presence of hy-
pergastrinemia causing hyperplasia of the precursor enteroch-
romaffin-like (ECL) cells, whereas type 3 occurs sporadically 
and independently of gastrin.4 This classification is based on 
the clinical differences of epidemiological, pathophysiological, 
endoscopic, and histological features between each type that 
affects prognosis, management, and follow-up.9 Type 1 and 2 
gastric NET have indolent behaviors, but type 3 gastric NET 
may be life-threatening with a high risk of metastasis and tu-
mor-related death.7
In type 1 and 2 gastric NET, hypergastrinemia plays a cru-
cial role in the development of tumors.10 The ECL cells, locat-
ed in the corpus-fundus mucosa of the stomach, represent the 
major proliferative target of gastrin. Proliferation of the ECL 
Fig. 2.  Histological examination of the gastric neuroendocrine tumor. Hematoxylin and eosin staining (H&E stain) showed that tumor cells invaded into the submu-
cosal layer (A, ×40). The tumor was composed of uniform cells with round or ovoid nuclei and scanty eosinopohlic cytoplasm, proliferating in a trabecular or glandular 
pattern, which were absent of mitotic count (B, ×100). Immunohistochemical stating for chromogranin A was diffusely positive (C, ×40). The Ki-67 labeling index was 
less than 1% (D, ×100).
A  B
C  D
Fig. 3. Follow-up endoscopic findings. Esophagogastroduodenoscopy after 6 
months from diagnosis still showed multiple remnant gastric polyps.
434   
cells results in tumorigenesis of NET. Gastric NET arising 
from these conditions grows usually multicentric lesions. On 
the other hand, types 3 gastric NETs are “gastrin-independent” 
tumors that are rarely multiple.4
Endoscopically, type 1 gastric NET tumors are often found 
in the fundus of stomach and are mostly polypoid (78%), of 
small shape (size 5 to 8 mm), and are multicentric (68%; mean 
number, 3).11,12 Type 2 gastric NETs are also usually identified 
as small, often multiple, polypoid tumors (<1 cm in size) in 
fundus.13 On the contrary, a type 3 gastric NET is typically a 
large (>1 cm, 66%), solitary (96%) lesion, that grows from the 
gastric body/fundus, and occurs in the antrum, within the 
context of a normal gastric mucosa.14,15 In this case, the en-
doscopic findings of multicentric (>10 lesions), small (<2 cm) 
polypoid lesions in the gastric fundus resembled closely to the 
type 1 and 2 gastric NETs. However, the diagnosis of type 3 
gastric NET was clinically based on normal gastrin levels and 
the absence of evidence of gastric atrophy or significant peptic 
ulcers that are commonly seen with type 1 or 2 gastric NETs, 
respectively.
A few cases of multiple gastric NETs without hypergas-
trinemia have been reported. Some cases of multiple gastric 
NETs in MEN 1 patients without hypergastrinemia have been 
previously described.16-18 These cases suggest that the develop-
ment of gastric NET in MEN 1 patients arises not only from 
hypergastrinemia in ZES, but also from the genetic mutations 
of the MEN 1 gene, one of the tumor suppressor genes. Mori-
yama et al.19 first reported multicentric gastric NETs that have 
been classified as type 3. In this case, the patient concomitant-
ly had a pituitary tumor, an adenomatous goiter, and bilateral 
Warthin’s tumors. Although a possible predisposition to MEN 
1 is suspected, genetic mutations could not be found in all 
the exons of the MEN 1 gene that has been translated. To our 
knowledge, this is the second report of a multicentric type 3 
gastric NET. More aggressive characteristics, including lym-
phovascular invasion, were observed in our case.
Type 3 gastric NETs exhibit a more aggressive course than 
the type 1 and 2 gastric NETs. Most type 3 gastric NETs 
showed lymphovascular and deep wall invasion at the time 
of diagnosis.20 In other cases, 60% to 75% present with meta-
static disease, and tumor-related death occurs 28 months after 
diagnosis in 25% to 30% of cases.4,20 Thus, the therapeutic ap-
proach to type 3 gastric NETs should be managed surgically.9 
Only small (<10 mm), well differentiated (G1) type 3 gastric 
NETs limited to the submucosal layer have been treated ef-
ficaciously by endoscopic mucosectomy, in a retrospective 
analysis.15
In summary, we described the case of a 50-year-old wom-
an with multicentric type 3 gastric NET without hypergas-
trinemia, which was endoscopically similar to the type 1 and 2 
lesions but with more aggressive features, such as lymphovas-
cular invasion. It will be necessary to study various other cases 
in order to discover the pathogenesis, and develop therapeutic 
strategies. This case serves as a reminder to gastroenterologists 
who encounter NET cases in their clinical practice, that even 
if the NET is multiple, a diagnosis of type 3 NET should be 
considered so that a careful evaluation of atrophic status such 
as endoscopic findings, serologic biomarkers, and gastrin lev-
els can be conducted.
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